Gemcitabine Hydrochloride API

Name	Gemcitabine hydrochloride
Chinese name	盐酸吉西他滨
Cas Number	122111-03-9
Source	India
Qualifications	USDMF/-/-/-/-

Gemcitabine hydrochloride is an anti-tumor compound. In 1996, the US FDA approved gemcitabine hydrochloride produced by Lilly Corporation as a first-line drug for the treatment of pancreatic cancer, and in 1998 it was approved as a drug for the treatment of non-small cell lung cancer. Gemcitabine hydrochloride is a cell cycle specific drug, which is converted into active nucleoside diphosphate (dFdCDP) and nucleoside triphosphate (dFd P) through nucleoside kinase in the cell. dFdCDP inhibits ribonucleotide reductase, thereby reducing the amount of deoxynucleotides necessary for DNA synthesis and repair, especially dCTP. dFdCTP can compete with dCTP to bind to DNA, causing the masking chain to terminate, DNA breakage, and cell apoptosis. ESPAC-4 study shows that the use of gemcitabine + capecitabine after pancreatic ductal carcinoma can significantly improve the survival rate of patients. Gemcitabine hydrochloride is one of the most effective first-line drugs for the treatment of non-small cell lung cancer. It is also the current gold standard for the treatment of advanced pancreatic cancer. It has the advantages of high remission rate, prolonged survival and low side effects; especially it can effectively prolong the patient’s Life, improve the quality of life of patients. The sales of gemcitabine hydrochloride in China's sample hospitals in 2018 were 727 million yuan, and sales have remained stable in recent years.

Hot Tags: gemcitabine hydrochloride api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Deoxycholic Acid API, Ticagrelor API, Itraconazole Hydrochloride API, Paliperidone API, Ranolazine API, Oseltamivir Phosphate API

• Previous: Famciclovir API
• Next: Fluvastatin Sodium API